Biomarkers Archives - AIT BioscienceAIT Bioscience


Category Archives for Biomarkers

Antibody Drug Conjugate Analysis: How Partnering with a Bioanalytical CRO Can Ease Preclinical ADC Programs

By: Frank Spriggs, Ligand Binding Assay Group Leader, and Ashley Brant, Program Manager   The potential of antibody drug conjugates (ADCs) to provide targeted therapies for cancers and other devastating diseases have made them popular candidates for drug development programs. However, as we discussed recently in Drug Discovery and Development, the failure of several ADCs … read the full article » »

Other Categories: LC-MS/MS Methods, Ligand Binding Assays (LBA), Partnerships



Comments Off on Antibody Drug Conjugate Analysis: How Partnering with a Bioanalytical CRO Can Ease Preclinical ADC Programs


Critical Reagents Consideration for Ligand Binding Assays

Ligand binding assays (LBAs) are bioanalytical procedures commonly used to support biotherapeutic development. These assays are used for the characterization of pharmacokinetics, biomarkers, and/or immunogenicity.  LBAs, unlike classic LC-MS/MS, utilize the interactions of a biotherapeutic and proteins used as critical reagents to detect the analyte of interest.  Therefore, special considerations must be made in the … read the full article » »

Other Categories: ELISA, Immunoassay, Ligand Binding Assays (LBA)



Comments Off on Critical Reagents Consideration for Ligand Binding Assays


Treating a Troublesome Biomarker Assay

By: Andrew Mayer   At AIT Bioscience we have established a sandwich ELISA optimized for the quantitative determination of human macrophage-colony stimulating factor (M-CSF), also known as colony stimulating factor-1 (CSF-1), from bulk critical reagents.  Up-regulation of M-CSF has been shown with viral infections, as well as many inflammatory diseases.  M-CSF can have a dual … read the full article » »

Other Categories: ELISA, Immunoassay

Tags: , , , ,

Comments Off on Treating a Troublesome Biomarker Assay